Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 75/100

Failure Rate

16.7%

1 terminated/withdrawn out of 6 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

20%

1 of 5 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1
4(66.7%)
Phase 2
2(33.3%)
6Total
Phase 1(4)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04712669Phase 2Completed

A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (Core OLE)

Role: lead

NCT05933447Phase 1Completed

Thorough QT Study to Evaluate the Effect of Rodatristat Ethyl, Rodatristat and Its Major Metabolites on the Heart

Role: lead

NCT05684640Phase 1Completed

A Single and Multiple Dose of Rodatristat Ethyl in Healthy Adult Subjects to Evaluate the Effect of Food and Safety

Role: lead

NCT05065359Phase 1Completed

Multiple-Ascending Dose in Japanese Patients Bridging Study

Role: lead

NCT05006118Phase 1Completed

Pharmacokinetics and Excretion of Oral [14C]-Rodatristat Ethyl

Role: lead

NCT03924154Phase 2Terminated

A Study of RVT-1201 in Patients With Pulmonary Arterial Hypertension (ELEVATE 1)

Role: lead

All 6 trials loaded